Register Login
Register to leave comments
  • News bot March 12, 2026, 12:13 p.m.

    📋 THERIVA BIOLOGICS, INC. (TOVX) - Financial Results

    Filing Date: 2026-03-12

    Accepted: 2026-03-12 08:10:35

    Event Type: Financial Results

    Event Details:

    THERIVA BIOLOGICS, INC. (TOVX) Reports the reporting period Financial Results THERIVA BIOLOGICS, INC. (TOVX) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 13056
      • planned for 2026
      • anticipated including enrolling the expected number of patients in each trial; the Company’s ability to complete clinical trials on time and achieve the desired results and benefits; the Company’s ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for the specific indications; acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s products; developments by competitors that render such products obsolete or non-competitive; the Company’s ability to maintain license agreements; the continued maintenance and growth of the Company’s patent estate; the Company’s ability to continue to remain well financed; and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024
      • planned for 1H 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 1.06K 1.44K $-384.00 -26.59%
    Noncurrent Assets Property Equipment Net 222.00 270.00 $-48.00 -17.78%
    Current Liabilities Accounts Payable 1.01K 859.00 $155.00 +18.04%
    Operating Costs And Expenses Total Operating Expenses 24.05K 26.35K $-2.29K -8.71%
    Operating Costs And Expenses Loss From Operations 24.05K 26.35K $-2.29K -8.71%
    Other Income Interest Income 287.00 697.00 $-410.00 -58.82%
    Income Tax Benefit Net Loss 23.74K 25.65K $-1.91K -7.46%
    Income Tax Benefit Net Loss Per Share 2.08 19.03 $-16.95 -89.07%
    Prepaid Expenses and Other Current Assets 1.06K 1.44K $-384.00 -26.59%
    Property and Equipment, Net 222.00 270.00 $-48.00 -17.78%
    Other Assets 82.00 75.00 $7.00 +9.33%
    Accounts Payable 1.01K 859.00 $155.00 +18.04%
    Total Operating Expenses 24.05K 26.35K $-2.29K -8.71%
    Loss from Operations 24.05K 26.35K $-2.29K -8.71%
    Interest Income 287.00 697.00 $-410.00 -58.82%
    Net Loss 23.74K 25.65K $-1.91K -7.46%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: THERIVA BIOLOGICS, INC.
    • Ticker Symbol: TOVX

Search

News categories